Jenna Matthews
Gerontology · Saint Peters, MONPI 1689210924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,636, more than ten times the $28 reported in 2021. Among gerontology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$501
- Travere Therapeutics, Inc.$500
- Amgen$441
- AstraZeneca$347
- Bayer$227
- OPKO Pharmaceuticals, LLC$221
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,936100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 27 | $501 |
| Travere Therapeutics, Inc. | 20 | $500 |
| Amgen(2 entities) | 23 | $441 |
| AstraZeneca | 16 | $347 |
| Bayer | 16 | $227 |
| OPKO Pharmaceuticals, LLC | 18 | $221 |
| Boehringer Ingelheim | 8 | $168 |
| Vifor Pharma, Inc. | 8 | $165 |
| Calliditas Therapeutics US Inc. | 6 | $163 |
| GSK | 9 | $155 |
| Novartis | 6 | $128 |
| Novo Nordisk | 5 | $103 |
| Vantive US Healthcare LLC | 2 | $101 |
| ANI Pharmaceuticals, Inc. | 4 | $93 |
| Mallinckrodt Hospital Products Inc. | 4 | $89 |
| Ardelyx, Inc. | 3 | $85 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $74 |
| Akebia Therapeutics Inc | 4 | $72 |
| Fresenius USA Marketing, Inc. | 3 | $67 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Baxter Healthcare | 1 | $27 |
| Recor Medical Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Lemaitre Vascular, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Athena Bioscience, LLC | 1 | $16 |
| Johnson & Johnson | 1 | $11 |
How this compares
$3,946 in reported general payments places this provider in the 90th percentile of 175 gerontology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 29 | $36,677 |
| FarxigaDapagliflozin Propanediol | 16 | $10,755 |
| Calcitriol | 74 | $1,313 |
| Hydralazine Hcl | 27 | $315 |
| Ondansetron OdtOndansetron | 16 | $112 |
| Carvedilol | 12 | $110 |
| Metoprolol Tartrate | 15 | $89 |
| Furosemide | 16 | $54 |
| Hydrochlorothiazide | 13 | $42 |
| Losartan Potassium | 15 | $26 |
| Bumetanide | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $221 | $36,67729 claims |
| AstraZenecaFarxiga | $347 | $10,75516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 gerontology providers in Missouri.
Other gerontology in Saint Peters
- Julie BoschertSaint Peters$569
- Tonia NeriniBevier$29K
- Melissa DusenberryKansas City$8K
- Kelly DaltonSpringfield$8K
- Laura TullisKansas City$7K
- Marissa SaengsamranSaint Louis$6K
- Matthew RobertsBridgeton$6K
- Amy GuanSaint Louis$5K
- Kayla WeissSaint Louis$5K
- Robin BobinmyerHumansville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.